Midgard Science

Harbour BioMed

Shanghai, China harbourbiomed.com From their website, Nov 2026

Work here? Claim this listing

About

Harbour BioMed is a biopharmaceutical company focused on discovering and developing novel antibody therapeutics. It serves global partners from R&D centers in China, the United States, and Europe, with work spanning antibody discovery platforms, clinical development, and strategic collaborations.

Services

  • Harbour Mice® antibody technology platform

    Generates fully human monoclonal antibodies in H2L2 and heavy chain-only (HCAb) formats.

  • Single Cell Technology Platform

    Provides a full single B cell cloning process including enrichment, separation, screening, sequencing, recombinant antibody production, and verification.

  • HBICE® bispecific antibody technology

    Uses HCAb-based immune cell engagers to generate flexible bispecific formats for different mechanisms of action.

  • HCAb PLUS™ technology

    Provides modality solutions for developing innovative multi-specific medicines across disease areas.

  • Generative AI HCAb Model

    Uses the Hu-mAtrIx™ AI platform to support fully human HCAb model development and accelerate therapy generation.

  • Clinical Development & Medical Services

    Delivers integrated clinical development from first-in-human studies through pivotal registration studies and post-marketing studies.

  • Co-development

    Shares design, execution, and risk of clinical trials with global partners.

  • Technology Service

    Provides technology support through fee-for-service and FTE arrangements.

3 more services
  • Technology License
  • Asset License
  • Strategic Collaboration

Capabilities

Assays and studies
  • Antibodies
  • Rodent models
  • Bispecifics
  • Small molecules
  • NGS
  • Single B cell cloning
6 more
  • Single B cell separation
  • Antibody binding screening
  • Functional in-chip screening
  • Single-cell antibody sequencing
  • High-throughput recombinant antibody production
  • Antibody verification
Scale and capacity
  • 150+ partners
  • 400+ projects
  • 20+ IND/clinical stage
  • 140+ partners
  • 380+ projects
  • Over 100 senior scientists
Therapeutic areas
  • Immunology
  • Oncology
  • Immuno-oncology
  • Weight management

Instruments and platforms

  • Optofluidic technology
  • Next-generation sequencing

Modalities and species

Modalities
  • Small molecule
  • Antibody
  • Bispecific
  • ADC
Species and models
  • Murine CD138+ plasma cell
  • Single B cell
  • Mammalian display libraries
  • Yeast display libraries
  • Phage display libraries

Details

Founded
2016
Team
Over 100 scientists
Based in
Shanghai, China
Sites
  • Beijing, China
  • Suzhou, China
  • Hong Kong, China
  • Natick, MA, United States of America
  • Rotterdam, Netherlands
Serves
Global, China, United States, Europe

Public records

Parent company
Harbour BioMed Therapeutics Limited · KY GLEIF

Similar labs